{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:29:47Z","timestamp":1786120187349,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/wnf.0b013e318237b2c7","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T04:18:36Z","timestamp":1321676316000},"page":"258-259","source":"Crossref","is-referenced-by-count":7,"title":["The Efficacy of Low-Dose Aripiprazole Treatment for Trichotillomania"],"prefix":"10.1097","volume":"34","author":[{"given":"Norio","family":"Yasui-Furukori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.psychres.2008.07.015","article-title":". Cross-cutting issues and future directions for the OCD spectrum.","volume":"170","author":"Hollander","year":"2009","journal-title":"Psychiatry Res"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.brat.2004.06.010","article-title":". Trichotillomania: impact on psychosocial functioning and quality of life.","volume":"43","author":"Diefenbach","year":"2005","journal-title":"Behav Res Ther"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1176\/ajp.148.3.365","article-title":"Characteristics of 60 adult chronic hair pullers.","volume":"148","author":"Christenson","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biopsych.2007.05.019","article-title":". Systematic review: pharmacological and behavioral treatment for trichotillomania.","volume":"62","author":"Bloch","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/070674370905400507","article-title":". Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments.","volume":"54","author":"Ravindran","year":"2009","journal-title":"Can J Psychiatry"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v64n0110","article-title":"An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.","volume":"64","author":"Stewart","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/da.20395","article-title":"Reversal of trichotillomania with aripiprazole.","volume":"25","author":"Jefferys","year":"2008","journal-title":"Depress Anxiety"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2710.2009.01051.x","article-title":". Improvement of restless legs syndrome and trichotillomania with aripiprazole.","volume":"34","author":"Virit","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1017\/S1092852900022719","article-title":". The paradox of quetiapine in obsessive-compulsive disorder.","volume":"10","author":"Tranulis","year":"2005","journal-title":"CNS Spectr"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","article-title":". Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.","volume":"67","author":"Gao","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/0269881108099423","article-title":". Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.","volume":"24","author":"Diniz","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R12-11-20210203","first-page":"55","article-title":"Role of dopamine systems in obsessive-compulsive disorder (OCD): implications from a novel psychostimulant-induced animal model.","volume":"51","author":"Szechtman","year":"1999","journal-title":"Pol J Pharmacol"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v66n0107","article-title":". The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.","volume":"66","author":"Connor","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S1461145705005365","article-title":". Case series on the use of aripiprazole for Tourette syndrome.","volume":"8","author":"Murphy","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","article-title":". Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts.","volume":"18","author":"Budman","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/da.20303","article-title":". Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.","volume":"25","author":"Storch","year":"2008","journal-title":"Depress Anxiety"},{"key":"R17-11-20210203","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1254\/jphs.FP0050144","article-title":". Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.","volume":"99","author":"Matsushita","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"R18-11-20210203","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":". Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J Clin Psychopharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201111000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:36Z","timestamp":1786047816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201111000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318237b2c7","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}